Lovastatin and Coadministered Antihypertensive/Cardiovascular Agents

Hypertension and hypercholesterolemia frequently coexist and may require concomitant drug treatments. The efficacy and safety profile of lovastatin given in the presence of antihypertensive medication was evaluated using patient subgroups identified in the Expanded Clinical Evaluation of Lovastatin (EXCEL) Study. The EXCEL study examined 8, 245 patients with moderate hypercholesterolemia randomly assigned either to a group treated with lovastatin (20-80 mg daily) or to a group given placebo for 48 weeks. After adjustment for patient characteristics, pairwise comparisons were made between patients taking no antihypertensive agents (n=3, 772) and those taking either calcium antagonists (n=446), selective β1-adrenergic receptor blockers (n=326), nonselective β-adrenergic receptor blockers (n=219), potassium-sparing diuretics (n=187), thiazide diuretics (n=126), or angiotensin converting enzyme inhibitors (n=171). The placebo-corrected dose-dependent effect of lovastatin on the percent change from baseline in low-density lipoprotein cholesterol was not attenuated in any subgroup and was slightly enhanced in the calcium antagonist subgroup (−29% to −44%, p=0.06) when compared with patients taking no antihypertensive agents (−24% to −40%); this difference, however, was only of borderline significance. Patterns of lovastatin-induced increase in high-density lipoprotein cholesterol and decrease in triglycerides were not consistently different among the subgroups. Examination of mean changes in serum transaminases, mean changes in creatine kinase, and the proportion of patients discontinuing therapy for clinical adverse experiences did not indicate the presence of an interaction. In conclusion, there was no evidence for an attenuation of the lovastatin-induced changes in lipids and Hpoproteins or of an alteration in the safety profile of lovastatin when administered concurrently with commonly used antihypertensive agents.